Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in ...

Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary ...

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...

Somiya Adrees is a writer at GameRant. Her gaming journey began at a young age with classics like Super Mario Bros., Sonic the Hedgehog, and Disney's Aladdin in Nasira's Revenge (all of which she ...

An international team of scientists headed by researchers at the University of Edinburgh, has created a complete map showing how hundreds of possible mutations in a key cancer gene, CTNNB1, influence ...

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors. The authors attempted ...

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants. The study, published in Cancer ...

INCA033989 targets mutCALR in ET patients with Type 1 CALR mutations, showing promise in early trials with rapid, durable hematological responses and a favorable safety profile. CALR mutations are ...

Nearly all (90%) of essential thrombocythemia (ET) patients treated with INCA033989 at the higher dose achieved a hematologic response (HR) with 83.3% achieving a complete HR Molecular responses were ...